Y-Intercept (HK)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Y-Intercept (HK)’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.16M	Sell	4,996 -5,305	-51%	-$1.31M	0.03%	936
2026 Q2	$2.48M	Buy	+10,301	New	+$2.26M	0.05%	586
2026 Q1	–	Sell	-6,242	Closed	-$1.06M	–	1807
2025 Q4	$1.06M	Buy	+6,242	New	+$957K	0.02%	955
2025 Q2	–	Sell	-9,721	Closed	-$1.21M	–	1832
2025 Q1	$1.21M	Buy	9,721 +7,090	+269%	+$925K	0.08%	340
2024 Q4	$324K	Sell	2,631 -10,068	-79%	-$1.19M	0.02%	911
2024 Q3	$1.41M	Sell	12,699 -11,622	-48%	-$1.27M	0.09%	305
2024 Q2	$2.6M	Buy	+24,321	New	+$2.67M	0.14%	180
2024 Q1	–	Sell	-3,377	Closed	-$415K	–	1570
2023 Q4	$415K	Buy	3,377 +1,372	+68%	+$171K	0.04%	681
2023 Q3	$260K	Sell	2,005 -4,069	-67%	-$542K	0.03%	822
2023 Q2	$753K	Buy	+6,074	New	+$817K	0.08%	395
2021 Q4	–	Sell	-5,058	Closed	-$659K	–	728
2021 Q3	$659K	Buy	5,058 +3,457	+216%	+$522K	0.12%	269
2021 Q2	$284K	Buy	+1,601	New	+$277K	0.07%	415
2021 Q1	–	Sell	-5,345	Closed	-$880K	–	700
2020 Q4	$880K	Buy	+5,345	New	+$796K	0.37%	55

Other funds holding JAZZ

LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.8B AUM 33.92% 1-Year Est. Return

Boston Trust Walden Boston, Massachusetts $12.4B AUM 21.62% 1-Year Est. Return

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Polaris Capital Management Boston, Massachusetts $953M AUM 27.74% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Y-Intercept (HK)'s JAZZ Position: Q3 2026 in Review

Y-Intercept (HK) reduced its Jazz Pharmaceuticals (JAZZ) stake by 51% in Q3 2026, selling an estimated $1.31M and leaving 4,996 shares worth $1.16M. The position accounts for 0.03% of the portfolio, ranked #936.

Y-Intercept (HK) first reported a position in JAZZ in Q4 2020 and has held it in 13 quarters since. The position peaked at $2.6M in Q2 2024. 331 funds tracked by Wall St. Rank hold JAZZ as of Q3 2026.

Y-Intercept (HK) held 4,996 shares of Jazz Pharmaceuticals worth $1.16M as of Q3 2026.
Y-Intercept (HK) sold 5,305 Jazz Pharmaceuticals shares in Q3 2026, an estimated $1.31M.
Jazz Pharmaceuticals made up 0.03% of Y-Intercept (HK)'s portfolio in Q3 2026, its #936 holding.
Y-Intercept (HK) first reported a position in Jazz Pharmaceuticals in Q4 2020 and has held it in 13 quarters since.
Y-Intercept (HK)'s Jazz Pharmaceuticals position peaked at $2.6M in Q2 2024.
331 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.